普通外文研报
Classys Inc: Risk Reward Update
研报英文原文证据摘录
Classys Inc: Risk Reward Update
UpdateM
RiskRisk RewardReward– Classys- ClassysInc (214150.KQ)Inc (214150.KQ)
RF device sales are rising but HIFU device sales are a drag; EW
PRICE TARGET W55,000 EQUAL-WEIGHT THESIS
We derive our price target (base case) from a DCF model to best capture the company's ▪Exports accounted for 67% of total sales
sustainable growth potential over the longer term. We assume a 9.3% cost of equity (beta in 2025.
1.05, risk-free rate 3.0% and risk premium 6.0%) and 4.0% terminal growth and FCF growth. ▪In 2025, existing Ultraformer franchise
Reflecting strong growth outlooks for skin tightening device markets (8.5% growth seen (HIFU brand for exports) device unit exports
from 2021 to 2029), we believe our long-term growth assumption is justified. were flat, but the new RF device Volnewmer
exports grew c.60% YoY. W77,313
rate the shares EW relative to ourConsensus Price Target Distribution W55,000 W95,000.00 ▪We coverage. We believe medical beauty device MS PT
Source: Refinitiv, Morgan Stanley Research Mean Morgan Stanley Estimates makers need to launch new products every
three to four years to sustain good growth,
but note it is difficult to predict future
product launches or successes. Also, margin
RISK REWARD CHART will likely decrease due to the acquisition of
MedSystems (a distributor in Brazil) in
March 2026.
KRW
W98,000W98,000(+110.98%)W98,000(+110.98%)(+110.98%)
Consensus Rating Distribution
95% Overweight
5% Equal-weight
75000 0% Underweight
MS Rating
W55,000W55,000(+18.41%)W55,000(+18.41%)(+18.41%)
50000 W46,450W46,450W46,450 Source: Refinitiv, Morgan Stanley Research
25000 Risk Reward Themes
W31,000W31,000(-33.26%)W31,000(-33.26%)(-33.26%)
Contrarian: Negative
View descriptions of Risk Rewards Themes here
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器